Keywords: Elan, Celgene, Abraxane, Eatson, Shire, Adderall X, USA, Patent settlement, Challenge

Elan and Celgene settle over Abraxane; Watson re-challenges Shire Adderall XR patent

Article | 28 February 2011

Print This

Ireland-based Elan (NYSE: ELN) says a subsidiary has entered into a settlement and license agreement with Celgene (Nasdaq: CELG) resolving ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in